Technology

Japanese | English
Into a New Stage of Development of Antibacterial Technology

Bacteria cause infections all over the world. Bacteria with acquired resistance to antibiotics pose public health problems that need urgent action. We have developed a anew antibacterial mechanism of action on the basis of bacterial structures and growth processes.

This technology is based on basic research that has thus far been conducted for a long period. In addition, it has been supported by Program for Creating Start-ups from Advanced Research and Technology (2012-2013), Ministry of Education, Culture, Sports, Science and Technology and Strategic Foundational Technology Improvement Support Operation (2012-2014), Ministry of Economy, Trade and Industry.
Using this technology thus developed, we aim to achieve “Global environment-friendly phylactic technology, production of safe food, and society of clean living and coexistence with living organisms.”

This technology is an original technology with a new antibacterial mechanism.

New Antibacterial Nano-particles

We have created an antibacterial acrylic nanopolymer as a totally new antibacterial means.
New Antibacterial Nano-particles

Nano CAME's New Technology

We focused on the cell wall of bacteria and bacterial growth process. Most bacteria have cell walls. Similar to the maintenance of the shape of human bones, bacteria has an important mechanism of maintaining their structures by keeping the internal pressure low (8 to 20 atmospheres). When bacteria keep growing, cell walls also repeat growth and reproduction.

Antibacterial Nanoparticles created by Nano Came exert their effects by adsorbing to the cell wall.

Antibacterial Nanoparticles have a high affinity for the sugar chain peptide surface layer of the cell wall and inhibit the synthesis of the cell wall in local areas to which Antibacterial Nanoparticles have adsorbed.

Antibacterial Nanoparticles created by Nano Came exert their effects by adsorbing to the cell wall.

The cell wall grows in the areas where Nanoparticles have not adsorbed. This causes unbalanced growth in these areas as compared to the areas to which Nanoparticles have adsorbed (location of conjugation) and makes it impossible to maintain the internal pressure, leading to autolysis.

Autolysis due to adsorption of a nanoparticle

The autolysis of Staphylococcus aureus, induced by Nano-particles (movie)

New antibacterial technology
The idea of reversal:Born from "manufacturing" that is close to fungi
World's first technology;Nanoparticles simply attach to the cell wall

Induces autolysis of bacteria

ナノ粒子が吸着することによる自己融解

Biodegradable antibacterial nanoparticles Electron microscope image

Staphylococcus aureus rupture(movie)

Produced by Dr. Shoichi Shirotake, previous professor of Grad. Sch. Med., Yokohama City University

Characteristics of New Technology

These nanoparticles that evoke apoptotic effects in bacteria are the first technology of its kind in the world, and we have filed an application for patent.

Conventional antibacterial technologies have allowed the occurrence of resistant bacteria due to the widespread use of antibiotics, i.e., an additional risk of infection. Moreover, inorganic antibacterial technologies have been associated with uncertainties regarding stable product supply and have demanded consideration of the impact of rare metals used in these technologies on living organisms and the environment. In contrast, this new technology induces autolysis of the bacterial cells without the use of rare metals. This technology has the following characteristics.
  • It does not lead to the occurrence of resistant bacteria, and its effect is sustained.
  • It does not require rare metals and ensures a stable supply.
  • It ensures safety in the body and does not damage the environment.

Experimental Example

1. MIC Table

Pathogens MIC Results (μg/mL)
Nano-particles D•Gly Nano-particles D•Arg Nano-particles D•Asp Nano-particles D•Ala Antibiotic ABPC Rubbing alcohol
Staphylococcus aureus 50 50 50 50 0.25> 15000
Staphylococcus aureus 50 50 50 50 2 60000
Multiple drug-resistant and methicillin-resistant Staphylococcus aureus 100 100 50 50 >128 60000
Multiple drug-resistant and methicillin-resistant Staphylococcus aureus 50 50 50 50 >128 60000
Enterococcus 50 50 25 50 0.5 240000
Multiple drug-resistant and vancomycin-resistant Enterococcus 25 50 25 25 2 60000
Multiple drug-resistant and vancomycin-resistant Enterococcus 25 50 25 25 1 120000
Streptococcus
(formerly milleri group)
25 50 25 25 0.25> 60000
Streptococcus pneumonia 12.5 12.5 12.5 12.5 0.25> 30000
Streptococcus pyogenes 12.5 12.5 12.5 12.5 0.25> 15000
Peptostreptococcus 6.3 12.5 6.3 6.3 0.25> 15000
Corynebacterium diphtheria 25 25 12.5 12.5 0.25> 15000
Propionibacterium acnes 12.5 12.5 12.5 12.5 0.25> 60000

2. Induction of Autolysis of Multiple Drug-resistant VRE by Antibacterial Nano-particles (SEM × 15000)

2. Induction of Autolysis of Multiple Drug-resistant VRE by Antibacterial Nano-particles (SEM × 15000)

3. Induction of Autolysis of VSE by Antibacterial Nano-polymer (SEM × 15000)

3. Induction of Autolysis of VSE by Antibacterial Nano-polymer (SEM × 15000)
To the top of this page